Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 5/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236389 | 1.00 | KMT2A (0.46) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL5481340 | 0.81 | MEN1 (0.52) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL5481343 | 0.81 | MEN1 (0.52) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL3988188 | 0.79 | G6PD (0.58) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL3988193 | 0.79 | G6PD (0.58) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL27718581 | 0.77 | MEN1 (0.53) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL11350178 | 0.77 | G6PD (0.72) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL11226874 | 0.76 | MEN1 (0.48) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL11226868 | 0.76 | MEN1 (0.48) | KMT2AAKR1B10AKR1B1MEN1LMNA | |
| SCHEMBL23872369 | 0.76 | GABRA1 (0.69) | KMT2AAKR1B10AKR1B1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402361-B1 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6,9-DIFLUORO-11-HYDROXY-16-METHYL-17-PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17-CARBOTHIOATE AND INTERMEDIATES | GENERICS UK LTD (GB) | 2020-04-15 | — | — | EP | disclosed |
| EP-2402360-B1 | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates | GENERICS UK LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| WO-2015199626-A1 | STABLE AEROSOL FORMULATIONS OF β2- ADRENERGIC AGONISTS | WORLD MEDICINE İLAÇ SANAYİ VE TİCARET ANONİM ŞİRKETİ (TR) | 2015-12-30 | — | — | WO | disclosed |
| US-8841442-B2 | Process for preparing fluticasone propionate/furoate | CADILA HEALTHCARE LIMITED (IN) | 2014-09-23 | — | — | US | disclosed |
| US-20140148593-A1 | PROCESS FOR PREPARING FLUTICASONE PROPIONATE/FUROATE | CADILA HEALTHCARE LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| US-20130172587-A1 | Process for the Preparation of Fluticasone Propionate | GENERICS [UK] LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| US-8344168-B2 | Process for the preparation of fluticasone propionate | GENERICS (UK) LIMITED (GB) | 2013-01-01 | — | — | US | disclosed |
| EP-2044099-B1 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6 ,9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17 -PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | GENERICS UK LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| EP-2402360-A1 | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates | Generics (UK) Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402361-A1 | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates | Generics (UK) Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20090177001-A1 | NOVEL PROCESS AND INTERMEDIATES | GENERICS [UK] LIMITED (INCORPORATED IN THE UNITED KINGDOM] (GB) | 2009-07-09 | — | — | US | disclosed |
| EP-2044099-A2 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6 ,9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17 -PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | Merck Generics (UK) Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007144668-A2 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6, 9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17-PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | GENERICS [UK] LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172587-A1 | Process for the Preparation of Fluticasone Propionate | CYP17A1, NR5A1, CYP4F3 | KMT2A 3275/4885AKR1B10 513/4885AKR1B1 206/4885 |
| US-20090177001-A1 | NOVEL PROCESS AND INTERMEDIATES | CYP17A1, NR5A1, CYP21A2 | KMT2A 3636/4885AKR1B10 399/4885AKR1B1 193/4885 |
| US-20140148593-A1 | PROCESS FOR PREPARING FLUTICASONE PROPIONATE/FUROATE | CYP4F3, CYP3A5, CYP51A1 | KMT2A 3457/4885AKR1B10 747/4885AKR1B1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.